InsidersTradesSigma
Follow the ProQR Therapeutics N.V. share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). The latest transaction was disclosed on 13 July 2026 (Acquisition). Among the most active insiders: de Boer Daniel Anton. Every trade is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing treatments for genetic diseases. It specializes in RNA-based therapies to address hereditary disorders.